Posted by Michael Wonder on 06 Feb 2024
Arvinas and Pfizer’s vepdegestrant (ARV-471) receives FDA fast track designation for the treatment of patients with ER positive/HER2 negative metastatic breast cancer
6 February 2024 - Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the oestrogen receptor protein.
Arvinas and Pfizer today announced that the US FDA has granted fast track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with oestrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.
